Abbvie Inc
BMV:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
BMV:ABBV
Watchlist
Price: 4 140 MXN 3.04% Market Closed
Market Cap: 376.3B MXN
Section:
 

Relative Value

The Relative Value of one ABBV stock under the Base Case scenario is hidden MXN. Compared to the current market price of 4 140 MXN, Abbvie Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBV Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

6.5
P/S
P/S
Price to Sales
6.5
vs History
4
vs Industry
54
Median 3Y
5.7
Median 5Y
4.5
Industry
8.2
Forward
6.3
More Details
165.7
P/E
P/E
Price to Earnings
165.7
vs History
4
vs Industry
2
Median 3Y
62.7
Median 5Y
34.9
Industry
24.2
Forward
20.3
More Details
18.6
P/OCF
P/OCF
Price to OCF
18.6
vs History
17
vs Industry
10
Median 3Y
15.9
Median 5Y
10.6
Industry
23
More Details
23
P/FCFE
P/FCFE
Price to FCFE
23
vs History
15
vs Industry
10
Median 3Y
19.3
Median 5Y
17.2
Industry
25.5
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
0
Median 3Y
20.2
Median 5Y
15.4
Industry
3.3
More Details
7.5
EV/S
EV/S
Enterprise Value to Sales
7.5
vs History
4
vs Industry
42
Median 3Y
6.5
Median 5Y
5.4
Industry
8.6
Forward
7.2
More Details
10.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.6
vs History
6
vs Industry
37
Median 3Y
9.6
Median 5Y
7.6
Industry
10.5
More Details
16.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.1
vs History
12
vs Industry
8
Median 3Y
14.5
Median 5Y
11.2
Industry
6.1
Forward
17.2
More Details
22.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
22.8
vs History
17
vs Industry
6
Median 3Y
21.8
Median 5Y
16.5
Industry
6.6
Forward
17.8
More Details
21.6
EV/OCF
EV/OCF
Enterprise Value to OCF
21.6
vs History
17
vs Industry
8
Median 3Y
18.3
Median 5Y
13
Industry
8.8
More Details
22.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.9
vs History
17
vs Industry
7
Median 3Y
19.2
Median 5Y
13.4
Industry
6.8
More Details
4.8
EV/IC
EV/IC
Enterprise Value to IC
4.8
vs History
4
vs Industry
32
Median 3Y
3.6
Median 5Y
3
Industry
5.7
More Details

Multiples Across Competitors

ABBV Competitors Multiples
Abbvie Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Abbvie Inc
BMV:ABBV
389B MXN 6.5 165.7 16.1 22.8
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 256 727 549 -17 630 396.1 -17 300 817.5 -17 262 306.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 036 074.3 -161 768.4 -196 438.5 -194 196.9
US
Amgen Inc
NASDAQ:AMGN
175.4B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
150.4B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.8B USD 10.1 32.1 23.5 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 069.8 -528.2 -575.1 -559.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.9B USD 5.9 18.3 17.5 19.9
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.4 1 204.9 162.5 197
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.3 55.4 56.9
P/S Multiple
Revenue Growth P/S to Growth
US
Abbvie Inc
BMV:ABBV
Average P/S: 26 433 250.9
6.5
9%
0.7
IL
C
Can Fite Biopharma Ltd
TASE:CANF
256 727 549
140%
1 833 768.2
FR
Pharnext SCA
OTC:PNEXF
34 036 074.3
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 069.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Abbvie Inc
BMV:ABBV
Average P/E: 189.4
165.7
89%
1.9
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 630 396.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 768.4 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 204.9
N/A N/A
NL
argenx SE
XBRU:ARGX
32.3
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Abbvie Inc
BMV:ABBV
Average EV/EBITDA: 39.8
16.1
14%
1.1
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 300 817.5 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 438.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.5
N/A N/A
NL
argenx SE
XBRU:ARGX
55.4
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Abbvie Inc
BMV:ABBV
Average EV/EBIT: 46
22.8
30%
0.8
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 262 306.3 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 196.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197
N/A N/A
NL
argenx SE
XBRU:ARGX
56.9
N/A N/A

See Also

Summary
ABBV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBV stock valuation using valuation multiples.
Wall Street Estimates
ABBV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.